Can ctDNA help us detect molecular residual disease and guide personalized treatment in patients with high-risk TNBC?
Our @TheTBCRC PREDICT-RD trial is investigating MRD-guided treatment with datopotamab deruxtecan (Dato-DXd) in patients with persistent ctDNA after neoadjuvant therapy and surgery.
Now open at @UNC_Lineberger and @ONealCancerUAB
Opening soon at @UChicago, @MontefioreNYC @MayoCancerCare & @DukeCancer
Thank you @PRIMR_MED for highlighting our study and helping raise awareness!
🎥 Watch below!
#bcsm
Our @TheTBCRC PREDICT-RD trial is investigating MRD-guided treatment with datopotamab deruxtecan (Dato-DXd) in patients with persistent ctDNA after neoadjuvant therapy and surgery.
Now open at @UNC_Lineberger and @ONealCancerUAB
Opening soon at @UChicago, @MontefioreNYC @MayoCancerCare & @DukeCancer
Thank you @PRIMR_MED for highlighting our study and helping raise awareness!
🎥 Watch below!
#bcsm
New video! 📢View quoted post on X
The PREDICT-RD trial studies whether MRD testing can catch early #breastcancer recurrence and guide personalized treatment for patients who still have TNBC remaining after surgery.
Watch:
primrmed.com/cancer-clinica…
@NateraGenetics @YAbdouMD @UNC_Lineberger